Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528441 | 1.00 | NPC1 (0.58) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2367798 | 1.00 | NPC1 (0.58) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3954455 | 1.00 | NPC1 (0.58) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2515281 | 0.89 | NPC1 (0.47) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL14498451 | 0.88 | NPC1 (0.44) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL23944688 | 0.85 | NPC1 (0.43) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL22365583 | 0.85 | NPC1 (0.43) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL19010013 | 0.82 | NPC1 (0.74) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL16325449 | 0.82 | NPC1 (0.56) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL21162136 | 0.82 | MAPT (0.47) | NPC1MAPTRAB9ASMN1; SMN2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024354-B | Preparation method of Rui Mi Buti Ni | 天津凯莱英制药有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-117024354-A | Preparation method of Rui Mi Buti Ni | 天津凯莱英制药有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-115141135-A | Preparation method of oxindole-acetic acid compound containing 3-bit chiral quaternary carbon center | 四川大学 | 2022-10-04 | — | — | CN | claimed |
| US-20250333400-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-30 | — | — | US | disclosed |
| US-20240368140-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| US-12129249-B2 | Method for producing optically active compound | DAY ONE BIOPHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4406609-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Day One Biopharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| EP-3439663-B1 | METHODS OF TREATING PEDIATRIC CANCERS | LOXO ONCOLOGY INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-109414442-B | Liquid preparation of compound | 洛克索肿瘤学股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11926619-B2 | Certain pladienolide compounds and methods of use | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2024-03-12 | — | — | US | disclosed |
| CN-117447464-A | Method for producing optically active compound | 首日生物制药公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20070117786-A1 | Intermediates for the preparation of tricyclic dihydropyrano-imidazo-pyridines derivatives | ALTANA PHARMA AG (DE) | 2007-05-24 | — | — | US | disclosed |
| EP-1567464-B1 | CATALYTIC HYDROGENERATION OF CARBON-HETEROATOM DOUBLE BONDS | SOLVIAS AG (CH) | 2007-04-18 | — | — | EP | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1697358-A1 | INTERMEDIATES FOR THE PREPARATION OF TRICYCLIC DIHYDROPYRANO -IMIDAZO -PYRIDINES DERIVATIVES | Altana Pharma AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| US-20060084820-A1 | Enantioselective, catalytic allylation of ketones and olefins | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-04-20 | — | — | US | disclosed |
| WO-2005058894-A1 | INTERMEDIATES FOR THE PREPARATION OF TRICYCLIC DIHYDROPYRANO -IMIDAZO -PYRIDINES DERIVATIVES | ALTANA PHARMA AG (DE) | 2005-06-30 | — | — | WO | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
| WO-2004031168-A2 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF OPTICALLY ACTIVE 3-AMINO-1-(2-THIENYL)-1-PROPANOL DERIVATIVES | LONZA AG (CH) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084820-A1 | Enantioselective, catalytic allylation of ketones and olefins | AKR1C2, TECR, AKR1C4 | NPC1 1539/4885MAPT 2756/4885RAB9A 4198/4885 |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | NPC1 3038/4885MAPT 908/4885RAB9A 1165/4885 |
| US-20240368140-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | PLAAT5, PLAAT3, PLAAT4 | NPC1 1734/4885MAPT 4316/4885RAB9A 704/4885 |
| US-20250333400-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | SNRPE, SNRPB2, DDX21 | NPC1 1630/4885MAPT 4458/4885RAB9A 2103/4885 |
| US-20070117786-A1 | Intermediates for the preparation of tricyclic dihydropyrano-imidazo-pyridines derivatives | CYP1A1, CYP3A4, CYP19A1 | NPC1 3091/4885MAPT 2451/4885RAB9A 3188/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | NPC1 3111/4885MAPT 1029/4885RAB9A 1183/4885 |
| US-12129249-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | NPC1 2691/4885MAPT 3660/4885RAB9A 1416/4885 |
| US-11926619-B2 | Certain pladienolide compounds and methods of use | PLAAT5, PLAAT3, PLAAT4 | NPC1 1734/4885MAPT 4316/4885RAB9A 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.